Guardant Health, Inc.

NASDAQ:GH

Medical - Diagnostics & Research

Healthcare
$145.14 +2.07%

+$2.67 today

Market cap
$19.64B
Beta
1.62
P/E (TTM)
-39.9
EPS (TTM)
-$3.30
52W Low $40.35High $135.00

Volume 1.50M

Average 2.21M

GH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Guardant Health, Inc.NASDAQ: GH

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $100.84M rose 12.1% year over year, ahead of the +7.6% change in trailing-twelve-month research & development. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at -0.9% a year.

Context

  • Research & development amounted to 37.1% of revenue in FY2025, down 10.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +12.1% holds above the trailing-twelve-month pace of +7.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$100.84M+4.5% QoQ
Last fiscal yearDec 2025
$364.19M+4.7% YoY
LTMSep 2026
$386.67M+7.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.1%——
1 year+4.7%——
3-year CAGR-0.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
364.19M USD
Year-over-year change
+4.7%
4-year CAGR
+8.5%

Research & Development vs competitors

How GH compares with its peers on the latest reported figures

  • GH's LTM Sep 2026 research & development of $386.67M is the 2nd highest of the 10 companies compared; the peer median is $55.69M.
  • Its year-over-year change of +7.6% is the 6th highest of 10, against a peer median of +9.5%.
  • Research & development amounts to 30.2% of revenue for GH, versus a peer median of 15.8%.
GH Competitors Peer median
Research & Development for GH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$787.38M +56.9%+25.4%29.1%
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
GRALGRAIL, Inc.LTM Jun 2026$190.99M -15.8%-15.9%115.6%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$55.69M +11.9%+23.1%17.4%
CSTLCastle Biosciences, Inc.LTM Mar 2026$53.69M +5.8%+4.9%15.8%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
BDSXBiodesix, Inc.LTM Mar 2026$12.42M +19.5%-2.9%12.9%
Peer median (excluding GH) $55.69M+9.5%+5.9%15.8%

Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue373.65M449.54M563.95M739.02M982.02M
Cost of Revenue122.91M156.33M227.05M289.8M349.01M
Gross Profit250.74M293.21M336.9M449.22M633.01M
Gross Margin67.1%65.2%59.7%60.8%64.5%
Research & Development263.22M373.81M367.19M347.75M364.19M
Selling, General & Admin398.52M463.78M451.03M545.06M706.07M
Operating Expenses661.74M837.59M901.62M892.81M1.07B
Depreciation & Amortization22.27M35.96M42.88M42.39M39.74M
EBITDA(359.62M)(614.91M)(433.31M)(390.12M)(373.91M)
EBITDA Margin-96.2%-136.8%-76.8%-52.8%-38.1%
Operating Income(411M)(544.38M)(564.73M)(443.59M)(437.25M)
Operating Margin-110.0%-121.1%-100.1%-60.0%-44.5%
Interest Income3.93M6.07M35.37M53.69M34.1M
Interest Expense2.58M2.58M2.58M2.58M3.9M
Other Income / Expenses26.53M(109.07M)85.96M8.51M19.71M
Income Before Tax(384.47M)(653.45M)(478.76M)(435.09M)(417.54M)
Pre-Tax Margin-102.9%-145.4%-84.9%-58.9%-42.5%
Income Tax Expense300K1.14M685K1.28M(1.26M)
Net Income(405.67M)(654.59M)(479.45M)(436.37M)(416.28M)
Net Margin-108.6%-145.6%-85.0%-59.0%-42.4%
EPS (Basic)(4.00)(6.41)(4.28)(3.56)(3.32)
EPS (Diluted)(4.00)(6.41)(4.28)(3.56)(3.32)
Weighted Avg Shares101.31M102.18M111.99M122.75M125.37M
Weighted Avg Shares (Diluted)101.31M102.18M111.99M122.75M125.37M

Guardant Health, Inc.

NASDAQ:GH

Intrinsic Alpha fair value

Locked

Current Price

$145.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.